C&CURE & ADVANCEMENTS
Cure & Advancements/November 10, 2026/3 min read

Special Stem Cells Show Promise in Protecting Transplanted Islets from Immune Attack

Researchers found that a type of immune-modulating stem cell, when transplanted alongside insulin-producing islets, helped protect grafts from rejection in laboratory models. The approach works by calming the body's immune response rather than suppressing it entirely.

Research summaryPubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsimmunotherapyadvancements

Key takeaways

  • Cotransplanting islets with AAT-MSCs—stem cells engineered to produce a protective protein—improved graft survival in humanized mouse models
  • The stem cells shifted immune responses by expanding regulatory B cells and reducing rejection-promoting immune signals
  • Transplanted islets retained more insulin-producing cells when given alongside these protective stem cells
  • This research addresses one of the major obstacles to islet transplantation: the immune system attacking and destroying the transplanted tissue

The Challenge: Rejection After Islet Transplant

For people with Type 1 diabetes, islet transplantation—receiving insulin-producing cells from a donor—offers potential to reduce or eliminate the need for insulin injections. However, the immune system often attacks and destroys these transplanted cells, limiting how long grafts survive. Scientists have long sought ways to protect transplanted islets without completely shutting down the immune system, which would leave patients vulnerable to infection.

A new study published in Diabetes explores whether a specific type of stem cell could solve this problem by helping the immune system tolerate the transplant rather than reject it.

The Approach: Immune-Modulating Stem Cells

Researchers tested human mesenchymal stromal cells (MSCs) that were engineered to produce extra amounts of alpha-1 antitrypsin (AAT), a protein known to have immune-calming properties. These AAT-MSCs were transplanted alongside human islets into specially designed mice with human immune systems.

The goal was to see whether these stem cells could shift the immune response in a way that protects the islet graft. Rather than broadly suppressing immunity, the researchers were looking for selective tolerance—a state where the immune system accepts the transplanted islets without becoming dangerously weakened.

What the Results Showed

Mice that received islets alone experienced typical rejection. In contrast, mice given islets plus AAT-MSCs showed markedly better blood sugar control and significantly longer graft survival over the 100-day study period.

The protective effect came through specific immune changes. Cotransplanted grafts triggered expansion of regulatory B cells—immune cells that calm inflammation rather than drive it. At the same time, harmful immune responses from T helper cells and cytotoxic T cells were suppressed. The transplanted islets also showed better preservation of insulin-producing tissue.

Researchers also observed lower levels of IgM antibodies, proteins the immune system makes to attack foreign material. In the laboratory, AAT-MSCs directly promoted the growth of regulatory B cells and reduced the ability of activated B cells to damage islet tissue.

Why This Matters

This research identifies a potential pathway to improve islet transplant success without relying on broad immunosuppression. By introducing immune-modulating stem cells alongside the transplant, researchers demonstrated they could shift the immune environment toward tolerance.

The findings were obtained in a laboratory model, so the next steps involve further testing to understand how well this approach might work in people. If successful, AAT-MSC cotransplantation could help make islet transplantation a more durable and practical option for Type 1 diabetes, though transplantation itself remains a specialized procedure requiring careful patient selection.

Evidence label

Source: Diabetes. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

From Type1Cure

Our own writing on the same ground.

More evidence-labeled coverage across the Type1Cure library.